<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037555</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1307</org_study_id>
    <nct_id>NCT02037555</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The
      purpose of this study is to determine the safety and effectiveness of human-derived
      antithrombin III (AT-III [Human]) supplementation prior to high-risk, non-emergency, cardiac
      surgery with cardiopulmonary bypass (CPB). A total of 404 adult subjects undergoing CPB who
      meet the study eligibility criteria were planned to be randomized to receive either AT-III
      (Human) or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this clinical study was to compare the percentage of subjects with
      any component of a 7 item major morbidity composite (postoperative mortality, stroke, acute
      kidney injury ([AKI]), surgical re-exploration, arterial or venous thromboembolic event,
      prolonged mechanical ventilation, or infection) between 2 groups of subjects randomly
      allocated to receive preoperative supplementation of AT-III (Human) (Antithrombin-III ([Human
      ]) or Placebo.

      The secondary objectives of this clinical study were the following:

        -  To compare postoperative antithrombin III (AT) levels at the Intensive Care Unit (ICU)
           admission between the AT-III (Human) treatment group and Placebo control group

        -  To compare the following perioperative outcomes between the AT-III (Human) treatment
           group and Placebo control group:

             -  Postoperative chest-drain blood loss in the first 12 and 24 hours after surgery

             -  Transfusion requirements

             -  Need for surgical re-exploration

             -  Low cardiac output syndrome

             -  Myocardial Infarction (MI)

             -  Stroke

             -  AKI

             -  Arterial or venous thromboembolic events

             -  Infections

             -  Prolonged mechanical ventilation (&gt;24 hours)

             -  All-cause postoperative mortality

             -  ICU stay duration

             -  Prolonged ICU stay (&gt;6 days)

             -  Length of hospital stay

      Additionally, safety objectives included the evaluation of AT III (Human) for clinical safety
      including adverse events (AEs), risks for bleeding, clinical laboratory testing, physical
      exam, and vital signs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2014</start_date>
  <completion_date type="Actual">January 25, 2018</completion_date>
  <primary_completion_date type="Actual">January 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Any Component of a Major Morbidity Composite</measure>
    <time_frame>Up to Day 30 +/- 4 days</time_frame>
    <description>Major morbidity composite defined as a composite of any one or more of the following:
Postoperative mortality (deaths occurring within 30 days of the operation or occurring during the primary hospitalization).
Stroke (clinical diagnosis of focal or global neurological deficit of abrupt onset caused by disturbance in cerebral blood supply).
Acute kidney injury (increase of serum creatinine levels to &gt;2.0 mg/dL and twice the baseline level or a new requirement for dialysis postoperatively).
Surgical reexploration (return to operating room because of bleeding, tamponade, graft occlusion or other cardiac reason).
Arterial or venous thromboembolic event (perioperative myocardial or mesenteric infarction, peripheral thromboembolism, acute coronary graft thrombosis, intracardiac thrombosis, deep vein thrombosis, pulmonary embolism).
Prolonged mechanical ventilation (&gt;24 hours).
Infection (deep sternal-wound infection and/or bloodstream infections).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>AT-III (Human)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-III (Human)</intervention_name>
    <description>AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.</description>
    <arm_group_label>AT-III (Human)</arm_group_label>
    <other_name>Antithrombin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride for Injection, United States Pharmacopeia</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female.

          2. At least 18 years of age.

          3. Subject needed non-emergency cardiac surgery with CPB.

          4. Types of cardiac operations permitted: complex/combined procedures (CABG+valve),
             double/triple valve repair/replacement, ascending aorta/aortic arch surgeries.
             Isolated CABG or single valve repair/replacements were allowed only if subject had
             received preoperative heparin &gt;2 days.

             - Following the incorporation of Protocol Version 4.0 (Amendment 3 dated 02 Apr 2015),
             this criterion was revised to include complex/combined procedures (CABG+valve),
             double/triple valve repair/replacements, ascending aorta/aortic arch surgeries
             (without baseline AT level restriction or preoperative heparin requirement). OR
             isolated CABG or single valve repair/replacements were allowed only if either (a) AT
             level was less than 80% OR (b) preoperative heparin was received ([UFH for at least 12
             hours; LMWH for more than 5 days).

          5. Subject had a baseline AT level of less than 80%.

               -  Following incorporation of Protocol Version 3.0 (Amendment 2 dated 02 Sep 2014)
                  this was changed to Subject had a Prescreening/Screening and baseline local lab
                  AT level of less than 80%.

               -  Following the incorporation of Protocol Version 4.0 (Amendment 3 dated 02 Apr
                  2015) this criterion was deleted and noted as &quot;Not applicable - intentionally
                  left blank for data management purposes (consistency in eCRF capture of
                  eligibility criteria historically).&quot;

          6. Subject had signed informed consent form.

          7. Subject was willing to comply with all aspects of the protocol, including blood
             sampling, for the total duration of the study.

        Exclusion Criteria:

          1. Subject needed emergency surgery.

          2. Subject needed heart transplantation.

          3. Subject needed the use of minimally invasive surgery.

          4. Subject had previous cardiac operation.

          5. Subject had infective endocarditis.

          6. Subject had thromboembolic events, stroke, or ST-elevated MI within 7 days of surgery.

          7. Subject had cardiogenic shock at the time of surgery.

          8. Subject had renal dysfunction: creatinine levels &gt;2 mg/dL or chronic dialysis.

          9. Subject had liver dysfunction: aspartate aminotransferase (AST), alanine
             aminotransferase (ALT) increase ≥2-fold above the upper-limit of local lab normal
             ranges.

         10. Subject had treatment with Clopidogrel® and Ticagrelor® within 5 days before surgery,
             Prasugrel® within 7 days before surgery, glycoprotein IIb/IIIa receptor blockers
             within 24 hours of surgery.

         11. Subject had treatment with new oral anticoagulants (Apixaban®, Rivaroxaban®,
             Dabigatran®) within 48 hours before surgery.

         12. Subject had Vitamin K antagonist therapy and an international normalized ratio (INR)
             &gt;1.3 on the day of surgery.

         13. Subject had platelet count &lt;120,000/μL.

         14. Subject had history or suspicion of a congenital or acquired coagulation disorder.

         15. Subject had history of anaphylactic reaction(s) to blood or blood components.

         16. Subject had allergies to excipients in the study drug.

         17. Subject had refused to receive allogenic transfusion of blood-derived products.

         18. Subject had received AT treatment within the last 3 months prior to Screening Visit.

         19. Subject was pregnant. Subject had participated in any another investigational study
             within the last 3 months prior to Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital at University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Ohio Heart</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of IN, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Health Nebraska Heart Medical Office</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Health Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research &amp; Education - The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Health</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Memorial City Medical Center</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic Surgical Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <results_first_submitted>January 24, 2019</results_first_submitted>
  <results_first_submitted_qc>January 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antithrombin</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02037555/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02037555/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AT-III (Human)</title>
          <description>Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
Placebo: 0.9% Sodium Chloride for Injection, United States Pharmacopeia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed and Operated On</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Subjects Receiving Study Treatment</population>
      <group_list>
        <group group_id="B1">
          <title>AT-III (Human)</title>
          <description>Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
Placebo: 0.9% Sodium Chloride for Injection, United States Pharmacopeia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="10.4"/>
                    <measurement group_id="B2" value="65.5" spread="12.80"/>
                    <measurement group_id="B3" value="66.1" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age Category</title>
              <category_list>
                <category>
                  <title>&lt;65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="382"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Any Component of a Major Morbidity Composite</title>
        <description>Major morbidity composite defined as a composite of any one or more of the following:
Postoperative mortality (deaths occurring within 30 days of the operation or occurring during the primary hospitalization).
Stroke (clinical diagnosis of focal or global neurological deficit of abrupt onset caused by disturbance in cerebral blood supply).
Acute kidney injury (increase of serum creatinine levels to &gt;2.0 mg/dL and twice the baseline level or a new requirement for dialysis postoperatively).
Surgical reexploration (return to operating room because of bleeding, tamponade, graft occlusion or other cardiac reason).
Arterial or venous thromboembolic event (perioperative myocardial or mesenteric infarction, peripheral thromboembolism, acute coronary graft thrombosis, intracardiac thrombosis, deep vein thrombosis, pulmonary embolism).
Prolonged mechanical ventilation (&gt;24 hours).
Infection (deep sternal-wound infection and/or bloodstream infections).</description>
        <time_frame>Up to Day 30 +/- 4 days</time_frame>
        <population>All subjects Treated and Operated On Excluding 4 Subjects with Non-verifiable Data</population>
        <group_list>
          <group group_id="O1">
            <title>AT-III (Human)</title>
            <description>Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
Placebo: 0.9% Sodium Chloride for Injection, United States Pharmacopeia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Any Component of a Major Morbidity Composite</title>
          <description>Major morbidity composite defined as a composite of any one or more of the following:
Postoperative mortality (deaths occurring within 30 days of the operation or occurring during the primary hospitalization).
Stroke (clinical diagnosis of focal or global neurological deficit of abrupt onset caused by disturbance in cerebral blood supply).
Acute kidney injury (increase of serum creatinine levels to &gt;2.0 mg/dL and twice the baseline level or a new requirement for dialysis postoperatively).
Surgical reexploration (return to operating room because of bleeding, tamponade, graft occlusion or other cardiac reason).
Arterial or venous thromboembolic event (perioperative myocardial or mesenteric infarction, peripheral thromboembolism, acute coronary graft thrombosis, intracardiac thrombosis, deep vein thrombosis, pulmonary embolism).
Prolonged mechanical ventilation (&gt;24 hours).
Infection (deep sternal-wound infection and/or bloodstream infections).</description>
          <population>All subjects Treated and Operated On Excluding 4 Subjects with Non-verifiable Data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 30 +/- 4 days</time_frame>
      <desc>Four subjects included in the participant flow table are excluded from safety and efficacy reporting. These 4 subjects, 2 from each treatment group, were subtracted from the 399 &quot;Dosed&quot; subjects planned for safety reporting and the 396 “Dosed and Operated on” subjects planned for efficacy reporting. The final population for safety reporting was 395 (AT-III n=199 [ie, 201–2] + Placebo n=196 [ie, 198–2]), and for efficacy reporting was 392 (AT-III n=198 [ie, 200–2] + Placebo n=194 [ie, 196–2]).</desc>
      <group_list>
        <group group_id="E1">
          <title>AT-III (Human)</title>
          <description>Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
Placebo: 0.9% Sodium Chloride for Injection, United States Pharmacopeia</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Heparin induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Arrhytmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hepatic ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac vein perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Postoperative delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Transfusion-related acute lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary arterial pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Decompressive craniectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Extravasation blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="199"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="199"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="199"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="199"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="61" subjects_affected="56" subjects_at_risk="199"/>
                <counts group_id="E2" events="42" subjects_affected="40" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="199"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="199"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="199"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="199"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="199"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="199"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="199"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="199"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="199"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperchloraemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="62" subjects_at_risk="199"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="199"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="199"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="199"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="199"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="199"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="199"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="199"/>
                <counts group_id="E2" events="51" subjects_affected="48" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="51" subjects_affected="50" subjects_at_risk="199"/>
                <counts group_id="E2" events="50" subjects_affected="48" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="199"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="199"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="52" subjects_affected="51" subjects_at_risk="199"/>
                <counts group_id="E2" events="61" subjects_affected="58" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A 12-month post-study period is reserved for a joint, multi-center publication of study results. After this period, individual sites may publish results provided that the Sponsor is allowed 30 days to review any proposed publication for removal of confidential, protected, and trademarked material prior to submission with an option to delay publication up to 60 days if needed to protect its interests. The Sponsor shall retain the option to receive acknowledgment for its sponsorship of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miquel Barceló, PhD</name_or_title>
      <organization>Grifols Therapeutics, LLC</organization>
      <phone>+34 935.712.368</phone>
      <email>Miquel.Barcelo@grifols.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

